Drug development for new therapies begins with research and discovery. To treat PWS (Prader-Willi syndrome) and SYS (Schaaf-Yang syndrome), we need to understand the differences between individuals with these conditions and typical individuals, right...
Acadia Pharmaceuticals has announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
A special blog contribution from Stephanie McDade. Last week Gibson rode a tricycle. She pedaled and steered on her own for a good five minutes on the sidewalk of our city block. This is real progress for a 8-year-old who doesn’t walk independently a...
Topics: Stories of Hope
You won’t want to miss these speakers at the 2023 FPWR Family Conference this October in Denver, CO.
Topics: Parents, Adults, Children 0-3, Advocacy
A special contribution by guest blogger Heather Osterman. Max came into the world with a bang...or more accurately, a limp body, not breathing, and blue. I went from being induced, since Max was quite cozy where he was, to a long labor, to an emergen...
Topics: Stories of Hope
FPWR’s grant program focuses on supporting innovative, high risk/high reward research in its early stages, with particular emphasis on supporting projects that will lead to new treatments for PWS.
Topics: News
FPWR is pleased to announce that we have recently awarded 13 project awards totaling $1.963M to support research aimed at advancing our understanding of Prader-Willi syndrome (PWS) and developing much-needed treatments. PWS is a complex genetic disor...
Topics: Research
Mice have long been the preferred mammal model in research labs due to their cost, size, and tractable genetics. Their behavioral simplicity, however, limits a researcher’s options for studying the component features that may serve as surrogate measu...
The Foundation for Prader-Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish biopharmaceutical company focused on developing innovative treatments for serious diseas...
Topics: News
